2,240 Shares in IQVIA Holdings Inc. $IQV Purchased by NBT Bank N.A.

NBT Bank N.A. purchased a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 2,240 shares of the medical research company’s stock, valued at approximately $602,000.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Apella Capital LLC lifted its stake in shares of IQVIA by 4.7% during the third quarter. Apella Capital LLC now owns 1,235 shares of the medical research company’s stock valued at $319,000 after acquiring an additional 55 shares during the period. Breakwater Capital Group boosted its holdings in IQVIA by 3.2% in the second quarter. Breakwater Capital Group now owns 2,073 shares of the medical research company’s stock valued at $401,000 after acquiring an additional 64 shares during the last quarter. Fortitude Family Office LLC increased its position in IQVIA by 17.2% in the third quarter. Fortitude Family Office LLC now owns 443 shares of the medical research company’s stock worth $119,000 after purchasing an additional 65 shares during the period. First Growth Capital LLC raised its holdings in IQVIA by 3.2% during the 1st quarter. First Growth Capital LLC now owns 2,173 shares of the medical research company’s stock worth $375,000 after purchasing an additional 68 shares during the last quarter. Finally, Chicago Partners Investment Group LLC raised its holdings in IQVIA by 1.5% during the 1st quarter. Chicago Partners Investment Group LLC now owns 4,635 shares of the medical research company’s stock worth $812,000 after purchasing an additional 70 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

Insiders Place Their Bets

In other IQVIA news, insider Keriann Cherofsky sold 558 shares of the business’s stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total transaction of $136,827.18. Following the transaction, the insider owned 2,989 shares of the company’s stock, valued at $732,932.69. The trade was a 15.73% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider W. Richard Staub sold 5,500 shares of the company’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $232.68, for a total transaction of $1,279,740.00. Following the completion of the transaction, the insider owned 13,312 shares in the company, valued at approximately $3,097,436.16. This represents a 29.24% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 15,581 shares of company stock valued at $3,796,021 in the last quarter. Company insiders own 1.70% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Stifel Nicolaus increased their price objective on shares of IQVIA from $276.00 to $303.00 and gave the company a “buy” rating in a report on Wednesday, October 14th. Truist Financial reaffirmed a “buy” rating and issued a $329.00 price objective (up from $300.00) on shares of IQVIA in a research note on Monday, September 28th. William Blair raised shares of IQVIA to a “strong-buy” rating in a report on Tuesday, July 28th. Rothschild & Co Redburn upped their target price on shares of IQVIA from $284.00 to $287.00 and gave the company a “buy” rating in a research report on Wednesday, July 29th. Finally, Evercore lifted their price objective on IQVIA from $275.00 to $290.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 6th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $278.75.

IQVIA Stock Performance

IQV stock opened at $279.47 on Friday. The business’s 50-day moving average price is $263.98 and its two-hundred day moving average price is $216.43. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18. The firm has a market cap of $46.00 billion, a PE ratio of 34.67, a P/E/G ratio of 2.45 and a beta of 1.17. IQVIA Holdings Inc. has a 1-year low of $154.50 and a 1-year high of $282.98.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.03 by $0.12. The company had revenue of $4.37 billion during the quarter, compared to the consensus estimate of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%. The company’s revenue for the quarter was up 8.7% compared to the same quarter last year. During the same period in the prior year, the company earned $2.81 earnings per share. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. As a group, research analysts forecast that IQVIA Holdings Inc. will post 11.54 earnings per share for the current year.

About IQVIA

IQVIA Holdings Inc is a global provider of technology, analytics and contract research services for the life sciences industry. The company helps pharmaceutical, biotechnology and medical device organizations develop, commercialize and improve products by combining healthcare data with advanced analytics, consulting and technology-enabled services.

Its offerings include clinical research and trial management, real-world evidence, healthcare data and analytics, regulatory and safety services, technology platforms, and commercial solutions.